Exploration of the pneumocandin biosynthetic gene cluster based on efficient CRISPR/Cas9 gene editing strategy in Glarea lozoyensis

被引:2
|
作者
Jiang, Kaili [1 ]
Jin, Yating [1 ]
Luo, Pan [1 ]
Wang, Xinxin [1 ]
Zhang, Yuanwei [1 ]
Shi, Tianqiong [2 ]
Chen, Jingjing [3 ]
Song, Ping [2 ]
Lu, Ling [1 ]
机构
[1] Nanjing Normal Univ, Coll Life Sci, Jiangsu Engn & Technol Res Ctr Microbiol, Jiangsu Key Lab Pathogens & Ecosyst, Nanjing, Peoples R China
[2] Nanjing Normal Univ, Sch Food Sci & Pharmaceut Engn, Nanjing, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Inst Mat Med, State Key Lab Bioact Subst & Funct Nat Med, NHC Key Lab Biosynthesis Nat Prod,CAMS Key Lab Enz, Beijing 100050, Peoples R China
基金
中国国家自然科学基金;
关键词
Glarea lozoyensis; Pneumocandin B 0; CRISPR/Cas9; Dual sgRNAs; SULFUR PROTEIN SUBUNIT; ZALERION-ARBORICOLA; RESISTANCE; CARBOXIN; TRANSFORMATION; DISCOVERY; PRECURSOR;
D O I
10.1016/j.ijbiomac.2024.135220
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Pneumocandin B0 (PB0) is a lipopeptide produced by the fungus Glarea lozoyensis. The existing challenges with the low-yield and the extended-fermentation cycle emphasize necessity for strain improvement. In this study, we optimized conditions to obtain high-quality protoplasts and screened effective selection markers, leading to the construction of three CRISPR/Cas9 gene editing systems. Utilizing a constitutive Cas9 expression recipient strain, combined with dual sgRNAs targeting, we achieved highly efficient editing of target genes. We successfully knocked out 10 genes within the pneumocandin putative biosynthetic gene cluster and analyzed their roles in PB0 production. Our findings reveal that 4 of 10 genes are directly involved in PB0 production. Specially, the deletion of gltrt or gl10050 resulted in reduced PB0 production, while the absence of glhyp or glhtyC led to the complete loss of PB0 biosynthesis. Notably, the deletion of glhyp caused the silencing of nearly all cluster genes, whereas overexpression of glhyp led to a 2.38-fold increase in PB0 production. Therefore, this study provides the first comprehensive exploration of the functions of 10 genes within the pneumocandin putative biosynthetic gene cluster. Our findings provide valuable technical strategies for constructing bioengineering strains with purposefully enhanced PB0 production.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing
    Chen, Xin-Zhu
    Guo, Rong
    Zhao, Cong
    Xu, Jing
    Song, Hang
    Yu, Hua
    Pilarsky, Christian
    Nainu, Firzan
    Li, Jing-Quan
    Zhou, Xin-Ke
    Zhang, Jian-Ye
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [42] CRISPR/Cas9 Gene Editing of HeLa Cells to Tag Proteins with mNeonGreen
    Surve, Sachin
    Sorkin, Alexander
    BIO-PROTOCOL, 2022, 12 (10):
  • [43] Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing
    Sinclair, Frazer
    Begum, Anjuman A.
    Dai, Charles C.
    Toth, Istvan
    Moyle, Peter M.
    DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2023, 13 (5) : 1500 - 1519
  • [44] Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing
    Frazer Sinclair
    Anjuman A. Begum
    Charles C. Dai
    Istvan Toth
    Peter M. Moyle
    Drug Delivery and Translational Research, 2023, 13 : 1500 - 1519
  • [45] Current applications and future perspective of CRISPR/Cas9 gene editing in cancer
    Si-Wei Wang
    Chao Gao
    Yi-Min Zheng
    Li Yi
    Jia-Cheng Lu
    Xiao-Yong Huang
    Jia-Bin Cai
    Peng-Fei Zhang
    Yue-Hong Cui
    Ai-Wu Ke
    Molecular Cancer, 21
  • [46] Generating Recombinant Avian Herpesvirus Vectors with CRISPR/Cas9 Gene Editing
    Tang, Na
    Zhang, Yaoyao
    Pedrera, Miriam
    Chang, Pengxiang
    Baigent, Susan
    Moffat, Katy
    Shen, Zhiqiang
    Nair, Venugopal
    Yao, Yongxiu
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2019, (143):
  • [47] Synthetic Vehicles for Encapsulation and Delivery of CRISPR/Cas9 Gene Editing Machinery
    Carboni, Valentina
    Maaliki, Carine
    Alyami, Mram
    Alsaiari, Shahad
    Khashab, Niveen
    ADVANCED THERAPEUTICS, 2019, 2 (04)
  • [48] Therapeutic Editing of the TP53 Gene: Is CRISPR/Cas9 an Option?
    Mirgayazova, Regina
    Khadiullina, Raniya
    Chasov, Vitaly
    Mingaleeva, Rimma
    Miftakhova, Regina
    Rizvanov, Albert
    Bulatov, Emil
    GENES, 2020, 11 (06) : 1 - 17
  • [49] How CRISPR/Cas9 Gene Editing Is Revolutionizing T Cell Research
    Johansen, Kristoffer Haurum
    DNA AND CELL BIOLOGY, 2022, 41 (01) : 53 - 57
  • [50] Therapeutic status and the prospect of CRISPR/Cas9 gene editing in multiple myeloma
    Hong, Lemin
    Zhang, Chenlu
    Jiang, Yijing
    Liu, Haiyan
    Huang, Hongming
    Guo, Dan
    FUTURE ONCOLOGY, 2020, 16 (16) : 1125 - 1136